Skip to content

MR-HIFU for Bone Metastases

Magnetic Resonance-Guided High Intensity Focused Ultrasound for Palliation of Painful Skeletal Metastases - a Multicenter Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01964677
Enrollment
12
Registered
2013-10-17
Start date
2014-01-31
Completion date
2016-11-14
Last updated
2017-08-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bone Metastases, Cancer

Keywords

Magnetic Resonance Imaging (MRI), High Intensity Focused Ultrasound (HIFU)

Brief summary

The aim of this study is to evaluate effectiveness of the Philips Sonalleve MR-HIFU device for the palliation of pain in patients with bone metastases. Magnetic Resonance Imaging-guided High Intensity Focused Ultrasound (MR-HIFU) uses ultrasound to palliate pain caused by bone metastases. The main palliative mechanism of the method is due to local bone denervation, caused by the heat denaturation of the periosteum layer in the treated area. The importance of this therapy is that it offers a non-invasive, focal therapy, avoiding side-effects to surrounding normal tissue that occur with radiation therapy or the need for needle insertion as with radio-frequency(RF)ablation. The study hypothesis is that MR-HIFU will be effective in treating the pain associated with bone metastases

Interventions

Sponsors

Philips Medical Systems
CollaboratorINDUSTRY
Institute of Cancer Research, United Kingdom
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* radiologic evidence of bone metastases from any solid tumour * diagnosis of dominant painful bone metastasis * target lesion less than 8cm

Exclusion criteria

* primary bone tumours rather than metastases * Inability to tolerate stationary position during treatment * pregnancy * MRI incompatible metal implants

Design outcomes

Primary

MeasureTime frame
Pain response30 days post-treatment

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026